News on research and diagnostic development for pathogenic diseases.
Pivoting from a technology that it deemed wasn't robust enough, Confer Health is now designing a platform to enable broad-scale testing at home.
The platform, which was first developed to transmit flu data to the CDC, is expanding to multiple use cases and multiple users.
The test will expand the range of diagnostic options available to guide treatment of Plasmodium vivax malaria, which relapses.
The firm said that its Cobas CT/NG real-time PCR assay is the first available in the US for the testing of sexually transmitted infections on its 6800 and 8800 systems.
The financing will go toward development of the company's home-based testing technology, which will be initially targeted at fertility testing.
